INTRODUCTION
An emerging developmental framework for hematopoiesis posits that cells of the innate and adaptive immune system arise from a common lymphoid-primed multipotent progenitor (LMPP) lacking erythrocytic and megakaryocytic potential (Adolfsson et al., 2005; Laiosa et al., 2006a) . Genetic and molecular analyses of various lineage-determining transcription factors have enabled the assembly of contingent gene regulatory networks that promote the generation of either myeloid or lymphoid progeny from multipotent hematopoietic progenitors (Laiosa et al., 2006a; Laslo et al., 2008; Rothenberg and Taghon, 2005; Singh et al., 2005) . Although the transcription factors PU.1, Ikaros, Mef2c, E2A, and EBF1 have been implicated in regulating myeloid versus lymphoid cell fate choice (DeKoter and The existence of multipotent progenitors restricted to the generation of myeloid and lymphoid progeny was previously proposed on the basis of genetic analysis of the gene encoding PU.1 (Sfpi1) (Singh, 1996; Singh et al., 1999) . PU.1 is a member of the Ets family of transcription factors and is expressed in multiple lineages of the hematopoietic system, including MPPs (Nutt et al., 2005) . In the absence of PU.1, the development of myeloid and lymphoid lineages is severely impaired, whereas the generation of erythrocytes and megakaryocytes is largely unaffected (McKercher et al., 1996; Scott et al., 1994) . The expression of many myeloid (DeKoter et al., 1998) and lymphoid-specific genes Medina et al., 2004 ) is abolished in PU.1-deficient (Sfpi1 À/À ) hematopoietic progenitors. Graded amounts of PU.1 appear to regulate the development of myeloid and B lineage progeny, given that a low concentration of PU.1 induces the B cell fate, whereas a higher concentration promotes macrophage development at the expense of B cell generation (DeKoter and Singh, 2000) . In addition, elevating expression of PU.1 has been shown to inhibit early T cell development (Anderson et al., 2002) and promote macrophage differentiation (Laiosa et al., 2006b ). These results suggest that PU.1 expression needs to be constrained in MPPs in order to enable B lymphopoiesis in the bone marrow and T lymphopoiesis in the thymus. The molecular means by which this is achieved remains to be elucidated. In myeloid progenitors, PU.1 has been shown to induce and resolve a mixed lineage pattern of gene expression resulting in the generation of macrophages and neutrophils (Laslo et al., 2006) . In this cellular context, PU.1 is a component of a transcriptional regulatory circuit composed of the myeloid determinant C/EBPa and the counteracting repressors Egr1,2, Nab2, and Gfi1. High expression of PU.1 induces Egr2 and Nab2. Importantly, Egr2 functions in a feed-forward loop with PU.1 to activate macrophage-specific genes and with Nab2 to repress alternate lineage neutrophil genes, including Gfi1. Conversely, Gfi1 promotes neutrophil differentiation by antagonizing PU.1 and Egr activity, the former, presumably, via direct protein-protein interactions (Dahl et al., 2007) and the latter via transcriptional repression (Laslo et al., 2006) . Because PU.1 expression appears to be regulated by a positive autoregulatory loop (Okuno et al., 2005) , these results raised the possibility that Gfi1 could attenuate expression of PU.1 by antagonizing PU.1 activity in MPPs, thereby lowering its expression to promote the generation of lymphocytes at the expense of myeloid progeny.
Like PU.1, Gfi1 is expressed in multiple hematopoietic lineages, including MPPs (Hock et al., 2004; Zeng et al., 2004) . However, Gfi1 expression appears to be inversely correlated with that of PU.1 in hematopoietic cells. Gfi1 À/À animals are neutropenic; the granulocytic intermediates that develop in the bone marrow misexpress PU.1-regulated genes such as Csf1r (Hock et al., 2003) . Interestingly, the frequency of myeloid progeny is increased in the bone marrow of Gfi1 À/À mice, whereas the number of B lineage cells in the bone marrow and T lineage cells in the thymus are significantly reduced (Hock et al., 2003; Yucel et al., 2003) . Because high amounts of PU.1 function to induce myeloid development and Gfi1 activity is critical in early lymphocyte development, we considered whether PU.1 and Gfi1 might function in an antagonistic manner to regulate innate versus adaptive immune cell fate choice in MPPs as they do in orchestrating macrophage versus neutrophil development. Given that high amounts of PU.1 are inhibitory for early B and T cell development, we reasoned that the underlying basis might involve PU.1-mediated induction of the Egrs that could directly repress Gfi1 expression. Consistent with this possibility, the loss of Egr1 results in increased T lineage precursors in the thymus (Bettini et al., 2002) . Given the aforementioned findings, we hypothesized that a network composed of PU.1, Egrs, and Gfi1 might function in a recurrent manner to regulate myeloid versus lymphoid cell fate choice in MPPs.
As with Gfi1, the loss of the zinc-finger transcription factor Ikaros has profound consequences on the development of both B and T lineage cells (Wang et al., 1996) . Additionally, Ikaros has been implicated in the generation of LMPPs (Yoshida et al., 2006) . Interestingly, Ikaros-deficient (Ikzf1 À/À ) pro-B cells retain myeloid developmental potential and misexpress multiple myeloid-specific genes, including Csf1r (Reynaud et al., 2008) . These findings suggest similar roles for Ikaros and Gfi1 in promoting early B and T cell development and in repressing myeloid developmental potential. We therefore considered the possibility that Ikaros and Gfi1 may represent components of a regulatory network in which they collaborate to promote adaptive immune cell fates and repress innate immune cell fates in MPPs.
We designed a set of genetic and molecular experiments to test the existence of the proposed regulatory network controlling innate versus adaptive immune cell fates. We demonstrate that Gfi1 promoted B cell fate choice by antagonizing the expression of the gene encoding PU.1 and aspects of the myeloid geneexpression program in MPPs. Molecular analyses revealed that Gfi1 directly repressed the Sfpi1 gene by targeting the Sfpi1 promoter and a distal upstream regulatory element (URE). Consistent with our hypothesis, Egr transcription factors were shown to function in an opposing manner to Gfi1, given that they inhibited B cell development while enabling myelopoiesis. Finally, we showed that Ikaros positively regulated Gfi1 and antagonized the expression of PU.1 in MPPs. These data are consistent with a model whereby Ikaros and Gfi1 function within MPPs to inhibit myeloid lineage potential by attenuating PU.1 and Egr activity, thereby facilitating the specification of lymphoid cell fates.
RESULTS

Gfi1 Promotes B Cell Fate Choice Because Gfi1
À/À animals exhibit a decrease in the frequency of common lymphoid progenitors and an increase in granulocyte and macrophage progenitors (Zeng et al., 2004) , we examined whether Gfi1 functions to promote B cell fate specification and repress myeloid development in the context of a MPP. We isolated MPPs from wild-type (WT) and Gfi1 À/À mice (Figure S1A available online) and plated equivalent numbers on OP9 stroma under conditions that support the generation of both myeloid (Mac1 + ) and B lineage (CD19 + ) progeny. WT progenitors gave rise to both myeloid (21%) and B lymphoid cells (68%). In contrast, MPPs lacking Gfi1 were severely defective for B cell development in vitro ( Figure 1A and Figure S1B ). We note that the loss of Gfi1 in vivo impairs, but does not eliminate, B cell development (Hock et al., 2003) . We also performed gainof-function analyses to test whether an increased concentration of Gfi1 in MPPs enhanced the generation of B lineage progeny at the expense of myeloid precursors. Transduction of WT MPPs with a control vector (MIGR1) via coculture primarily generated Mac1 + cells. In contrast, MPPs transduced with a Gfi1 vector (MIGR1-Gfi1) generated a higher proportion of CD19 + progeny ( Figure 1B ). With limiting-dilution assays, MPPs transduced with Gfi1 were seen to give rise to B lineage progeny at a frequency nearly 3.5 times higher than their control counterparts ( Figure S1C ). These results demonstrate that Gfi1 promotes B cell fate choice at the expense of myeloid options in the context of MPPs.
Gfi1 Antagonizes PU.1 Expression in MPPs PU.1 expression is elevated in total bone marrow cells lacking Gfi1 (Hock et al., 2003) . We specifically analyzed the expression of PU.1 and other hematopoietic determinants in WT and Gfi1
MPPs. Whereas the expression of Ikaros and Gata1 were unaffected in Gfi1 À/À MPPs, PU.1 transcripts were elevated ( Figures   2A and 2B) . Moreover, the expression of the Csf1r gene, which is directly activated by PU.1 (Krysinska et al., 2007) , was increased in Gfi1 À/À MPPs (Figures 2A and 2B ). We note that Flt3 transcripts are reduced in Gfi1 À/À MPPs ( Figure 2B ), consistent with reduced Flt3 expression on the surface of Gfi1 À/À MPPs (Hock et al., 2004; Zeng et al., 2004) . We also assessed expression of c-fms and FcgRII and III on Gfi1 À/À MPPs by using flow cytometry. Like c-fms, the FcgRII and FcgRIII receptors are expressed on myeloid precursors and their genes are directly activated by PU.1. The loss of Gfi1 resulted in increased expression of c-fms, FcgRII, and FcgRIII in MPPs ( Figure 2C ). We note that the expression of Ly6G and Mac1, two cell-surface markers that are expressed on more mature myeloid cells, was not affected ( Figure S2A ). Thus, loss of Gfi1 results in elevated expression of PU.1 and its myeloid target genes in MPPs.
We evaluated the developmental potential of c-fms expressing MPPs to test whether they were biased toward myeloid fates ( Figure S2B ). Gfi1 À/À MPPs that were c-fms À had considerably lower B lineage developmental potential than WT MPPs ( Figure S2B ). Importantly, c-fms + MPPs lacking Gfi1 were further impaired in their ability to give rise to B lineage progeny. Therefore, B lineage potential may be impaired in Gfi1
MPPs as a consequence of enhanced myeloid potential. We predicted that augmented PU.1 expression in Gfi1
MPPs should result in enhanced macrophage potential. We analyzed Gfi1 À/À MPPs for their ability to undergo multilineage erythro-myeloid differentiation. The absence of Gfi1 resulted in $50% reduction in plating efficiency of MPPs relative to WT counterparts ( Figure 2D ). WT MPPs preferentially gave rise to granulocyte-macrophage colonies ($70%) and, to a lesser extent, macrophage (25%) and myelo-erythroid colonies (5%) ( Figure 2E ). In contrast, the preponderance of colonies generated from Gfi1 À/À MPPs contained macrophages (85%). No discernable difference was noted between WT and Gfi1
MPPs in the generation of myelo-erythroid colonies, suggesting a role for Gfi1 in lineage restriction subsequent to the specification of megakaryocyte and erythrocyte fates. Taken together, these data suggest a critical role for Gfi1 in constraining the expression of PU.1 in the context of two distinct cell fate choices: (1) macrophage versus neutrophil and (2) myeloid versus B cell.
PU.1 Heterozygosity Partially Rescues B Cell Development in Gfi1
À/À Mice
Given that the loss of Gfi1 results in enhanced expression of PU.1, we reasoned that this may partially account for the reduced B cell developmental potential of Gfi1 À/À MPPs. To test this possibility, we determined whether reducing the dosage of PU.1 would suppress the B cell developmental defect caused by the loss of Gfi1. As previously described (Hock et al., 2003) , loss of Gfi1 resulted in fewer committed B lineage cells (B220 + CD19 + ) in the bone marrow ( Figure 3A ). Combining PU.1 heterozygosity with the Gfi1 mutation led to a 2-fold increase in the frequency as well as the absolute numbers of committed B lineage cells ( Figures 3A and 3B ). In addition, there was a 2-fold increase in the number of pro-B cells (B220
). These results demonstrate that B lineage defects in Gfi1 À/À bone marrow can be partially suppressed by reducing Sfpi1 gene dosage.
To determine whether reduced Sfpi1 gene dosage increases the B lineage developmental potential of Gfi1 À/À MPPs, we quantitatively analyzed their cell fate outputs in vitro. We note that loss of one allele of Sfpi1 was associated with a decrease in c-fms, FcgRII, and FcgRIII expression on the cell surface of
). WT MPPs gave rise to B lineage cells at a frequency of $1/24, whereas loss of Gfi1 severely impaired the generation of such cells (1/1260) ( Figure 3C ). Importantly, we observed $3.5-fold increase (1/360) in the frequency of B lineage cells generated from Gfi1 increased expression of PU.1. Transduction of WT MPPs with a vector targeting PU.1 mRNA (MSCV-shPU.1) resulted in $70% reduction in PU.1 transcripts and its target gene Csf1r ( Figure 4A ). Reduced PU.1 expression impaired terminal myeloid differentiation, as evidenced by the accumulation of c-Kit + Mac1 + myeloid precursors ( Figure 4B ). This resembled the accumulation of similar myeloid precursors in the bone marrow of mice in which PU.1 expression is reduced by targeting an upstream distal enhancer (Rosenbauer et al., 2004) . Importantly, attenuation of PU.1 expression in WT MPPs resulted in a higher frequency of committed B lineage progeny (27%) and diminished Mac1 + precursors (52%) compared to control transductants ( Figure S4 Figure 4C ). These data establish that Gfi1-mediated antagonism of PU.1 expression in MPPs is used to regulate B versus myeloid cell fate choice.
Inhibition of Egr Activity Promotes B Cell Fate Choice
We have previously proposed that higher amounts of PU.1 antagonize Gfi1 expression via induction of the Egr's which directly bind to the Gfi1 promoter and repress its activity (Laslo et al., 2006 Figure 5A ). Limiting-dilution analyses revealed that blocking Egr activity in MPPs enhanced B cell development by more than an order of magnitude ( Figure 5B ). Thus, blocking Egr activity in MPPs has similar consequences on B cell development as enhancing Gfi1 expression ( Figure 1B) . We next used genetic interaction analyses to test for the functional cross-antagonism between the Egrs and Gfi1 in B cell development. Interestingly, we observed that the removal of Egr1 partially suppressed the B cell developmental defect observed in Gfi1 À/À mice ( Figure 5C and Figure S5A ). This paralleled the partial ''rescue'' of B cell development in Gfi1 À/À mice by reducing the dosage of PU.1 ( Figures 3A and 3B ). Egr1 and Egr2 function redundantly during macrophage differentiation (Laslo et al., 2006) . To test whether Egr1 and Egr2 also function redundantly in antagonizing the generation of B cells, we generated mice lacking both Egr1 and Egr2 by using a conditional Egr2 allele (Taillebourg et al., 2002) . This was necessary because Egr2 À/À mice die soon after birth (Swiatek and Gridley, 1993) and loss of Egr1 and Egr2 results in embryonic lethality. Using the Mx1-Cre transgene, we observed efficient excision of the Egr2 allele in total bone marrow cells 4 weeks after polyIC treatment ( Figure S5B ). Combined loss of Egr1 and Egr2 resulted in a $2-fold increase in the percentage of B lineage progeny in the bone marrow and a comparable reduction in myeloid precursors ( Figures S5B and S5C) . These results provide compelling genetic evidence in support of the hypothesis that Egrs antagonize B cell fate choice at the expense of myeloid options in MPPs.
Gfi1 Targets the Sfpi1 Promoter and URE Given that Gfi1 functions as a transcriptional repressor, we examined whether Gfi1 targets the Sfpi1 gene, which encodes PU.1. Bioinformatic analysis revealed conserved putative Gfi1 binding sites in the PU.1 promoter and the URE ( Figure S6A ). Intriguingly, these presumptive Gfi1 binding sites were in close proximity to PU.1 binding sites. PU.1 binding sites in the promoter and URE of the Sfpi1 gene have been implicated in a positive autoregulatory feedback loop (Okuno et al., 2005) . We considered the possibility that Gfi1 could repress the Sfpi1 gene by displacing PU.1 from its own promoter and URE. We performed electrophoretic mobility-shift assays (EMSAs) to determine whether PU.1 and Gfi1 recognize the predicted binding-site motifs in the promoter and URE. PU.1 and Gfi1 bound to their respective motifs in the URE with higher affinity than to the corresponding motifs in the promoter ( Figure S6B ). Given that the Gfi1 and PU.1 sites overlap within the URE, we tested whether the proteins compete for DNA binding. Competition reactions revealed PU.1 and Gfi1 displace each other when binding to the composite element in the URE ( Figure 6A ).
To determine whether Gfi1 and PU.1 bind to the URE in a reciprocal manner in vivo, we performed chromatin immunoprecipitation (ChIP) assays with a cell line that expresses an inducible PU.1 protein (PUER) (Walsh et al., 2002) . In the absence of tamoxifen (OHT), these cells express Gfi1 (Laslo et al., 2006) , which could be seen to crosslink to the URE ( Figure 6B ) as well as the PU.1 promoter ( Figure S6C, left panel) . A basal amount of crosslinking of PU.1 was also detectable at these regions ( Figure 6B and Figure S6C , left panel). Upon stimulation with OHT, PU.1 binding at the URE and promoter increased, whereas Gfi1 crosslinking was diminished ( Figure 6B and Figure S6C , left panel). Increased PU.1 binding accompanied by the loss of Gfi1 was also observed at the Csf1r promoter ( Figure S6C , right panel), consistent with recent findings implicating Gfi1 in the repression of the Csf1r gene (Zarebski et al., 2008) . Although induction of PU.1 activity resulted in downregulation of Gfi1, we did not observe reduced Gfi1 crosslinking to an autoregulatory site in the Gfi1 promoter (data not shown, Yucel et al., 2004) . Thus, loss of Gfi1 binding at the URE is likely a consequence of displacement by PU.1. Collectively, these data demonstrate that Gfi1 targets multiple regulatory regions within the PU.1 locus and suggest that it restrains PU.1 expression by interrupting an autoregulatory loop.
Apposed Gfi1 Motifs in PU.1 Target Sequences
To explore whether the molecular antagonism of PU.1 action by Gfi1 via apposed binding sites may occur at other loci, 
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we performed ChIP-on-chip assays by using a promoter array to identify PU.1 target genes in OHT-induced PUER cells. Bioinformatic analysis (see Experimental Procedures) revealed that 3170 PU.1 target sequences contained presumptive Gfi1 binding sites. Of these, 19% contained a putative PU.1 site within 10 bp of a Gfi1 site ( Figure S6D ). Interestingly, PU.1 and Gfi1 motifs were seen to overlap in nearly half of this subset of ChIP sequences. As a control, we generated a set of randomized DNA sequences in silico with the same base composition and length as the PU.1 target set. Comparison between PU.1-bound and randomized DNA sequences revealed a statistically significant difference given that only 9% (SD = 0.44) of randomized sequences contained presumptive binding sites for the two transcription factors separated by 10 bp or less. Strikingly, the most notable arrangement of presumptive PU.1 and Gfi1 binding sites consisted of ones in which the core motif of PU.1 (GGAA) and Gfi1 (AATC) overlapped by a single nucleotide ( Figure 6D , see Pim1). The fact that the same configuration was retained as a predominant feature in the randomized sequences, albeit at a substantially lower frequency, led us to consider the possibility that the large frequency of overlapping sites might be explained by compatibilities within the extended binding motifs of PU.1 and Gfi1. In fact, inspection of the Gfi1 binding site matrix revealed preferences for specific nucleotides flanking the core base pairs of the Gfi1 site that potentially encode PU.1 sites ( Figure 6D ). Detailed analysis of the Gfi1 binding matrix revealed a number of preferred PU.1 site configurations in relation to the Gfi1 core, as evidenced in both the PU.1 ChIP-on-chip and randomized DNA analysis ( Figure 6D ). These analyses suggest that a large number of PU.1 target genes may be repressed via competitive binding or proximal action of Gfi1.
Ikaros Regulates Gfi1 and Constrains PU.1 Expression
Given that Ikaros is required for B cell development and repression of myeloid potential, we examined whether its loss, like that of Gfi1, also results in the enhanced expression of PU.1 in MPPs. PU.1 and c-fms transcripts were increased in Ikzf1 À/À MPPs ( Figure 7A and Figure S7A ). In addition, the loss of Ikaros resulted in a substantial increase in the expression of both c-fms and FcgRII and III ( Figure 7B ). The similarities in the myeloid signature observed in Gfi1 À/À and Ikzf1 À/À MPPs suggested a potential relationship between Ikaros and Gfi1 activity in restraining myelopoiesis. Therefore, we sought to determine whether Ikaros activity was required for the expression of Gfi1 in MPPs. Utilizing a Gfi1-GFP reporter allele , we observed that the loss of Ikaros was associated with the generation of a subset of MPPs expressing lower amounts of GFP ( Figure 7C ). We note that a larger subset of Ikzf1 À/À MPPs expressed higher amounts of GFP relative to their control counterparts. These cells also expressed higher amounts of c-fms (data not shown) and may represent MPPs that are primed to the myeloid lineage (Ng et al., 2009 ). Bioinformatic analysis revealed several putative Ikaros binding sites in the Gfi1 locus. Interestingly, two such sites were positioned downstream of the Gfi1 gene in a $170 bp region that is duplicated ( Figure S7B ). EMSA and ChIP assays demonstrated that Ikaros bound these sites in vitro and in vivo ( Figures  S7C and S7D ). These data suggest that Ikaros directly promotes Gfi1 expression in a subset of MPPs.
DISCUSSION
Using Sfpi1 À/À hematopoietic progenitors, we have previously reported that a graded concentration of PU.1 regulates B lymphocyte versus macrophage cell fate choice (DeKoter and Singh, 2000) . Consistent with these findings, it has been reported that antagonizing the expression of PU.1 in differentiating mouse embryonic stem cells with siRNA enhances their B lineage developmental potential (Zou et al., 2005) . However, demonstrating a role for PU.1 dosage in innate versus adaptive cell fate ''choice'' in vivo has proven to be elusive. Using a sensitized genetic background, a null mutation in the Gfi1 locus, we show that reducing PU.1 concentration via a gene-dosage strategy results in enhanced B lymphopoiesis. Importantly, these results establish a role for PU.1 concentration in the regulation of myeloid versus B lymphocyte cell fate choice in vivo in the context of a MPP. Recent studies have revealed that reduced PU.1 expression by removal of a distal PU.1 enhancer resulted in a decrease, rather than an increase, in bone marrow-derived B lineage progeny in vivo (Rosenbauer et al., 2006) . In these animals, removal of the distal enhancer reduced PU.1 transcripts to less than 20% of WT MPPs. It may be that reducing PU.1 concentration to amounts observed in PU.1-enhancer-deficient animals is suboptimal for initiating the B cell program in MPPs. It is also possible that impaired B lymphopoiesis in these gene-targeted mice is a consequence of enhanced generation of neutrophil precursors (Rosenbauer et al., 2004) . Lowering the concentration of PU.1 in relation to C/EBPa has been shown to promote the generation of neutrophils (Dahl et al., 2003) . Furthermore, because PU.1 can negatively regulate the expression of Gfi1 via the Egrs (Laslo et al., 2006) , Gfi-1 expression is likely to be increased in MPPs of PU.1-enhancer-deficient animals. In this context, increased Gfi1 expression would function in concert with C/EBPa to promote neutrophil development. Nonetheless, our results demonstrate that PU.1 and Gfi1 have opposing roles in promoting myeloid versus B cell development and establish that these counteracting regulators function in a recurring manner to regulate cell fate choice in the innate as well as the adaptive immune systems.
How does Gfi1 restrain the expression of PU.1 in MPPs to specify the B cell fate? Previously, Gfi1 has been shown to interact with the PU.1 protein, and this protein-protein interaction has been suggested to inhibit PU.1 mediated transactivation (Dahl et al., 2007) . Although we cannot rule out the involvement of this protein interaction in antagonism of Sfpi1 gene expression by Gfi1, we show that Gfi1 directly competes for PU.1 binding in vitro and in vivo to autoregulatory sites in the PU.1 locus. We therefore propose that Gfi1 represses Sfpi1 gene activation by binding to DNA sites in the locus and disrupting a PU.1-dependent autoregulatory loop. Importantly, increased expression of PU.1 can induce Egr expression, and the latter represses Gfi1. Finally, Gfi1 has been shown to bind to its own promoter and function in a negative autoregulatory loop . Thus, the two autoregulatory feedback loops and the cross-antagonism between PU.1 and Gfi1 may generate alternate gene-expression states within this network that are driven by either higher PU.1 and Egr activity or higher Gfi1 activity. Gfi1 À/À MPPs are poised to differentiate along the myeloid lineage at the expense of the B lineage as a consequence of misexpression of PU.1 and other myeloid genes. In addition to the PU.1 locus, Gfi1 targets many myeloid genes, including Csf1r (Zarebski et al., 2008) . Accordingly, the absence of Gfi1 in MPPs may augment the expression of PU.1 target genes, such as Csf1r, via derepression. Our analysis of PU.1 target sequences has revealed an intriguing feature: a large number of PU.1 core motifs are embedded within the extended binding matrix for Gfi1. Therefore, robust activation of such PU.1 target genes would be dependent on displacement of Gfi1 repressor complexes with PU.1 activator complexes at these composite elements, and vice versa. We note that the predicted composite sites are found in a varied set of genes, including growth factors and their receptors, lineage-determining transcription factors, and histone-modifying enzymes. We envision that the antagonistic regulation of a large battery of genes by PU.1 and Gfi1 would have evolved more readily by selecting for favorable composite binding sites for the two factors rather than independent selective events that generate two separated sites. This may represent a general strategy for rapidly evolving counteracting regulatory modules by utilizing transcription factors whose individual binding motifs are compatible with the generation of overlapping composite elements. On the basis of the aforementioned data, we propose a transcriptional regulatory network (circuit diagram) that appears to function in a recurring manner to govern cell fate choice in the immune system. In MPPs, PU.1 is proposed to function in a graded manner to regulate B lymphoid versus macrophage cell fates. A higher concentration of PU.1 represents a primary input to the macrophage developmental program and can induce the Egrs (module a). These regulators activate both myeloid gene expression and the Id genes that inhibit E2A activity (module b) and consequently the priming of B-lymphoid developmental potential in MPPs (Dias et al., 2008) . A lower concentration of PU.1 along with Ikaros and E2A function as primary inputs to activate the B lymphoid program. These factors induce the B cell fate determinant EBF1 (module c) (Laslo et al., 2008 ). In our model, the reduced concentration of PU.1 that promotes B lymphoid development is achieved by Ikaros, in part, through the induction of Gfi1. Ikaros and Gfi1 constrain the expression of PU.1 while promoting the expression of B lymphoid genes. We note that Ikaros has been implicated in repression of the myeloid determinant C/EBPa (Reynaud et al., 2008; Ng et al., 2009 ). This repressive activity of Ikaros is likely to be important for B cell development, given that C/EBPa can reprogram committed B cells into macrophages (Laiosa et al., 2006a ).
An additional consequence of Ikaros and Gfi1-mediated repression of the myeloid program in MPPs could be to promote T cell developmental potential. Along these lines, Gfi1 activity appears to be critical for the generation of the earliest T lineage progenitors in the thymus (Yucel et al., 2003) . It is noteworthy that the loss of Ikaros and Gfi1 is associated with the increased expression of Id genes (Yucel et al., 2003; Ng et al., 2009) . These genes encode proteins that inhibit E2A family transcription factors that are required for early B and T cell development (Quong et al., 2002) . Conversely, we have demonstrated that high concentrations of PU.1 induce Id2 during macrophage differentiation (Laslo et al., 2006) . Similarly, increasing PU.1 expression in fetal thymic progenitors induces Id2 and aspects of the myeloid program (Franco et al., 2006) . These findings suggest a general mechanism by which Gfi1 and PU.1 could function in a counteracting and recurring manner to promote B and T lymphoid versus myeloid cell fates via the antagonistic regulation of Id genes. Consistent with our model, Egr1 has been identified as a positive regulator Id3 gene expression (Bain et al., 2001; Quong et al., 2002) . Loss of Egr1 results in an increase in the absolute numbers of the earliest T lineage progenitors (Bettini et al., 2002) . We note that multiple defects observed in Gfi1 À/À mice during T cell development, including reduced cellularity and impaired progression through the double-negative and double-positive stages of development, are partially rescued upon the loss of Egr1 in vivo (C.J.S. and H.S., unpublished data). These findings are also in keeping with our proposal that the Egrs and Gfi1 comprise a counteracting regulatory module that directs cell fate options or developmental transitions in multiple cellular contexts (Laslo et al., 2006) . On the basis of the above results, the Ids would represent an additional node within this module whose expression would be counteracted by Gfi1 to promote lymphopoiesis or induced by PU.1 and the Egrs to inhibit B and T cell potential. Our proposed core transcriptional network for lymphoid versus myeloid cell fate determination is derived from one that regulates macrophage versus neutrophil cell fate choice (Laslo et al., 2006) . In the former, Ikaros has replaced C/EBPa as a pivotal primary determinant, but the remaining circuit is conserved both with respect to the nature of the regulatory molecules and to their connectivity. The modified network architecture has two important evolutionary implications for the emergence of the adaptive immune system from an innate primordial precursor. First, it suggests that the conserved core network (Reynaud et al., 2008) . Molecular phylogenetic analysis of our network components and their connectivity will be necessary to test this evolutionary proposition.
EXPERIMENTAL PROCEDURES
Mice Sfpi1 +/À (Scott et al., 1994) , Egr1 +/À (Swiatek and Gridley, 1993) , Egr2 +/fl (Taillebourg et al., 2002) , Ikzf1 +/À (Wang et al., 1996) , and Gfi1 +/À mice have been previously described. The Gfi1 mutant allele represents a GFP knockin, and the mutant mice are phenotypically indistinguishable from previously described Gfi1 knockout animals (Karsunky et al., 2002) . Therefore, Gfi1 GFP/GFP mice are referred to as Gfi1 À/À in these studies. Wild-type C57BL/6 mice were purchased from the Jackson Laboratory. Mice were maintained in pathogen-free conditions in accordance with guidelines approved by the Institutional Animal Care and Use Committees of the University of Chicago.
Flow Cytometry and Cell Culture
Bone marrow single-cell suspensions washed in PBS containing 5 mM EDTA and 0.5% BSA were analyzed by flow cytometry with an LSRII (Becton Dickinson) and FlowJo software. The following antibodies conjugated to fluorescein isothiocyanate (FITC), phycoerythrin (PE), PerCPCy5.5, phycoerythrin-Cy7 (PE-Cy7), and allophycocyanin (APC) were used against cell-surface molecules outlined in Table S5 . DAPI was used for discriminating between viable and dead cells. MPPs were isolated and cultured as previously described (Medina et al., 2004) and analyzed for the presence of Mac1 + and CD19 + cells between days 7-12 by flow cytometry.
Retroviral Transduction
WT MPPs were isolated as described above and transduced by coculture with GFP (MIGR1), Gfi1 (MIGR1-Gfi1), or DEgr2 (MIGR1-DEgr) as previously described (DeKoter and Singh, 2000) . After 2 days, GFP + transductants were sorted and cultured on OP9 stroma in previously described B lineage conditions (Medina et al., 2004) and analyzed for the presence of Mac1 + and CD19 + cells by flow cytometry 7 days after sorting.
Plat-E packaging cells were transiently transfected with shRNA retroviral constructs targeting luciferase (MSCV-shLuciferase) or PU.1 (MSCV-shPU.1) with Fugene 6 reagent (Roche). WT or Gfi1 À/À MPPs were isolated as described above and transduced as previously described (Reynaud et al., 2008) and analyzed for the presence of Mac1 + and CD19 + cells by flow cytometry 10 days after sorting. shRNA targeting sequences are available upon request.
Gene-Expression Analysis RNA was isolated with TRIzol reagent (Invitrogen) and reverse-transcribed with a first-strand cDNA synthesis kit (GE Healthcare) in accordance with the manufacturer's instructions. Reverse-transcription products were serially diluted and amplified by PCR for semiquantitative analyses. Brilliant SYBR Green was used for quantitative PCR analyses on a Mx4000 system (Stratagene). Expression was normalized relative to the expression of Hprt. Primer sequences used for semiquantitative and quantitative PCR analyses are listed in Tables S1 and S2 .
Colony-Forming Assays
Clonogenic assays were performed by sorting $300 MPPs from WT or Gfi1
À/À mice in 3 ml of Methocult M3434 (Stem Cell Technologies) supplemented with 25 ng/ml of Flt3 ligand (R&D Systems). Approximately 100 MPPs were plated in duplicate in 35 mm petri dishes. After 8 days in culture, individual colonies were counted, subjected to cytospin, and analyzed for the presence of erythroid and/or myeloid colonies by Wright staining.
EMSA PU.1 and Gfi1 proteins were generated with the TNT coupled reticulocyte lysate system (Promega). IVT extracts were incubated for 30 min at RT with a-32 P-labeled double-stranded oligonucleotides representing an optimal Gfi1 (Gfi1 consensus), a high affinity PU.1 (lB) binding site, or sites in the PU.1 promoter and URE in a final volume of 20 ml of binding reaction buffer (10 mM Tris [pH 7.5], 50 mM NaCl, 3% Ficoll, 1 mM EDTA, 1 mM DTT, and 1 mg/ml of polydI:dC). Ikaros binding reactions were performed as previously described (Reynaud et al., 2008) . EMSA probes are listed in Table S4 .
ChIP
ChIP assays were performed in PUER cells treated with tamoxifen for 24 or 96 hr as previously described (Laslo et al., 2006) or EBF À/À cells with some modifications. In brief, 1 3 10 7 cells were crosslinked with 1% paraformaldehyde, sonicated, precleared, and incubated with 2 mg of a-IgG (sc-2027; Santa Cruz), a-PU.1 (sc-352; Santa Cruz), a-Gfi1 (sc-8558; Santa Cruz), preimmune, or a-Ikaros antiserum (Smale lab). Complexes were washed with low and high salt buffers, eluted, and reverse-crosslinked, and the DNA was precipitated. Immunoprecipitated DNA sequences were analyzed by qPCR (primer sequences used for ChIP analyses are listed in Table S3 ). For ChIP-on-chip, chromatin DNA samples were amplified by ligation-mediated PCR and hybridized on a MM8 RefSeq promoter chip (NimbleGen Systems).
Computational Analysis of PU.1 and Gfi1 Binding Sites Genomic coordinates for all fragments bound by PU.1 with high confidence as determined by NimbleScan (FDR score < 0.2) were extended by 500 bp upstream and downstream, and these sequences were retrieved. MotifLocator was used for analyzing all ChIP sequences to predict PU.1 (M01172) and Gfi1 (M00250) binding sites of quality t R 0.85. Algorithms were developed in Perl so that the arrangement and distribution of PU.1 and Gfi1 binding sites could be determined. Randomized sets of sequences were generated by matching the length and base composition of the DNA sequences obtained from the ChIP-on-chip data. Statistical analyses were based on 100 independent randomized runs.
SUPPLEMENTAL DATA
Supplemental Data include seven figures and five tables and can be found with this article online at http://www.cell.com/immunity/supplemental/ S1074-7613(09)00415-4.
